---
layout: default
title: Ritonavir
description: "Ritonavir çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚åˆæ­¥è­‰æ“šç­‰ç´š L4ï¼ŒåŒ…å« 3 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 149
evidence_level: L4
indication_count: 3
---

# Ritonavir

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L4</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>3</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Ritonavirï¼šå¾ HIV åˆ°çŒ¿å…ç–«ç¼ºä¹ç—…æ¯’æ„ŸæŸ“

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Ritonavir å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Ritonavir æ˜¯ä¸€ç¨® HIV è›‹ç™½é…¶æŠ‘åˆ¶åŠ‘ï¼ŒåŸæœ¬ç”¨æ–¼äººé¡å…ç–«ç¼ºä¹ç—…æ¯’ï¼ˆHIVï¼‰æ„ŸæŸ“çš„æ²»ç™‚ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**çŒ¿å…ç–«ç¼ºä¹ç—…æ¯’æ„ŸæŸ“ (Simian Immunodeficiency Virus Infection)** æœ‰æ•ˆï¼Œç›®å‰æœ‰ **å¤šç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | äººé¡å…ç–«ç¼ºä¹ç—…æ¯’ï¼ˆHIVï¼‰æ„ŸæŸ“ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | HIV infectious diseaseã€simian immunodeficiency virus infectionã€feline acquired immunodeficiency syndrome |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.92% |
| è­‰æ“šç­‰ç´š | L4 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. simian immunodeficiency virus infection</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.92%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Ritonavir æ˜¯ä¸€ç¨® HIV è›‹ç™½é…¶æŠ‘åˆ¶åŠ‘ï¼Œä¸»è¦ç”¨æ–¼ HIV æ²»ç™‚ã€‚ç›®å‰å®ƒé€šå¸¸ä½œç‚ºè—¥ç‰©å‹•åŠ›å­¸å¢å¼·åŠ‘ï¼ˆboosterï¼‰èˆ‡å…¶ä»–è›‹ç™½é…¶æŠ‘åˆ¶åŠ‘ï¼ˆå¦‚ darunavirã€lopinavirï¼‰ä½µç”¨ï¼Œä»¥æé«˜å…¶ä»–è—¥ç‰©çš„è¡€ä¸­æ¿ƒåº¦ã€‚

çŒ¿å…ç–«ç¼ºä¹ç—…æ¯’ï¼ˆSIVï¼‰æ˜¯ HIV çš„è¿‘è¦ªç—…æ¯’ï¼Œåœ¨éäººéˆé•·é¡å‹•ç‰©ä¸­å¼•èµ·é¡ä¼¼ AIDS çš„ç–¾ç—…ã€‚SIV æ˜¯ç ”ç©¶ HIV æ„ŸæŸ“å’ŒæŠ—ç—…æ¯’è—¥ç‰©çš„é‡è¦å‹•ç‰©æ¨¡å‹ã€‚ç”±æ–¼ SIV å’Œ HIV çš„è›‹ç™½é…¶å…·æœ‰çµæ§‹ç›¸ä¼¼æ€§ï¼Œé‡å° HIV è›‹ç™½é…¶çš„æŠ‘åˆ¶åŠ‘å° SIV ä¹Ÿå¯èƒ½å…·æœ‰æ´»æ€§ã€‚

æ–‡ç»ç ”ç©¶å·²è­‰å¯¦ï¼š
1. Ritonavir åœ¨é«”å¤–å° SIVmac239 å…·æœ‰æŠ‘åˆ¶æ´»æ€§
2. åŒ…å« ritonavir-boosted lopinavir çš„å¤šè—¥çµ„åˆç™‚æ³•å¯æœ‰æ•ˆæŠ‘åˆ¶ SIV æ„ŸæŸ“çš„æ†æ²³çŒ´é«”å…§ç—…æ¯’è¼‰é‡
3. SIV/SHIV å‹•ç‰©æ¨¡å‹æ˜¯è©•ä¼°æŠ—é€†è½‰éŒ„ç—…æ¯’è—¥ç‰©çš„é‡è¦å·¥å…·

### è‡¨åºŠè©¦é©—

ç›®å‰ç„¡é‡å° SIV æ„ŸæŸ“çš„äººé¡è‡¨åºŠè©¦é©—ï¼ˆSIV ä¸æ„ŸæŸ“äººé¡ï¼‰ã€‚

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [12709355](https://pubmed.ncbi.nlm.nih.gov/12709355/) | 2003 | Journal Article | Antimicrob Agents Chemother | SIVmac239 å° ritonavir çš„æ•æ„Ÿæ€§ï¼ˆEC50: 13 nMï¼‰ |
| [16973590](https://pubmed.ncbi.nlm.nih.gov/16973590/) | 2006 | Journal Article | J Virol | å››è—¥æŠ—é€†è½‰éŒ„ç—…æ¯’æ²»ç™‚åœ¨ SIV æ„ŸæŸ“ç¼çŒ´ä¸­çš„å¿«é€Ÿç—…æ¯’è¡°æ¸› |
| [22737073](https://pubmed.ncbi.nlm.nih.gov/22737073/) | 2012 | Journal Article | PLoS Pathog | é«˜å¼·åº¦ ART å¯é•·æœŸæŠ‘åˆ¶ SIV ç—…æ¯’è¼‰é‡ä¸¦é™åˆ¶ç—…æ¯’å„²å­˜åº« |
| [34903055](https://pubmed.ncbi.nlm.nih.gov/34903055/) | 2021 | Journal Article | mBio | å„˜ç®¡æœ‰æ•ˆçš„ ARTï¼Œæ…¢ç—…æ¯’æ„ŸæŸ“ä»æŒçºŒå­˜åœ¨æ–¼è…¦ä¸­ |
| [17350308](https://pubmed.ncbi.nlm.nih.gov/17350308/) | 2007 | Journal Article | Microbes Infect | SHIV-pr æ§‹å»ºåŠå…¶å°è›‹ç™½é…¶æŠ‘åˆ¶åŠ‘æ•æ„Ÿæ€§çš„é«”å…§è©•ä¼° |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. feline acquired immunodeficiency syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.92%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.92%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.92%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.92%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬XXXXXXè™Ÿ | æ™®åˆ©ä»–è†œè¡£éŒ 150æ¯«å…‹ | è†œè¡£éŒ  | äººé¡å…ç–«ç¼ºä¹ç—…æ¯’ï¼ˆHIVï¼‰æ„ŸæŸ“ |

## å®‰å…¨æ€§è€ƒé‡

**ä¸»è¦è­¦èªï¼š**
- è—¥ç‰©äº¤äº’ä½œç”¨ï¼šRitonavir æ˜¯ CYP3A4 çš„å¼·æ•ˆæŠ‘åˆ¶åŠ‘ï¼Œèˆ‡å¤šç¨®è—¥ç‰©æœ‰é¡¯è‘—äº¤äº’ä½œç”¨
- è‚æ¯’æ€§
- è„‚è³ªä»£è¬ç•°å¸¸

**ç¦å¿Œç—‡ï¼š**
è«‹åƒè€ƒåŸå» ä»¿å–®

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**high-fat foods** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šAdministration with food may modestly affect the bioavailability of ritonavir from the various available formulations.  When the oral solution was given under nonfasting conditions, peak ritonavir con...
- å»ºè­°ï¼šRitonavir should be taken with meals to enhance gastrointestinal tolerability.

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**è–ç´„ç¿°è‰ï¼ˆè²«è‘‰é€£ç¿¹ï¼‰** ğŸ”´ Major
- å½±éŸ¿ï¼šè–ç´„ç¿°è‰é¡¯è‘—é™ä½ Ritonavir è¡€ä¸­æ¿ƒåº¦ï¼Œå¯èƒ½å°è‡´ HIV æ²»ç™‚å¤±æ•—
- å»ºè­°ï¼šçµ•å°ç¦æ­¢ä½µç”¨



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Hyperglycemia** ğŸŸ¡ Moderate
- New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, glucose intolerance, hyperglycemia, and some cases of diabetic ketoacidosis have been reported during postmarketing surveillance in HIV-infected patients treated with proteas...

**Hyperlipidemias** ğŸŸ¡ Moderate
- Hyperlipidemia has been observed in 10% of patients receiving ritonavir during clinical trials.  Increases of 30% to 40% from baseline have been reported for total cholesterol and 200% to 300% or more for triglycerides.  These effects have also been ...

**Heart Block** ğŸŸ¡ Moderate
- Ritonavir may prolong the PR interval in some patients.  Post marketing cases of second or third degree atrioventricular block have been reported.  Ritonavir should be administered cautiously in patients with underlying structural heart disease, pree...

**Hemophilia A** ğŸŸ¢ Minor
- There have been postmarketing reports of increased bleeding, including spontaneous skin hematomas and hemarthrosis, in types A and B hemophiliac patients treated with protease inhibitors.  However, a causal relationship has not been established.  In ...

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¢ Minor
- Hepatotoxicity, including jaundice, hepatitis and hepatic transaminase elevations exceeding five times the upper limit of normal, has been reported in patients receiving ritonavir alone and in combination with nucleoside reverse transcriptase inhibit...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
é€™å€‹é æ¸¬åœ¨ç§‘å­¸ä¸Šæ˜¯åˆç†çš„ï¼Œå› ç‚º SIV æ˜¯ HIV çš„è¿‘è¦ªç—…æ¯’ï¼Œritonavir å° SIV è›‹ç™½é…¶çš„æŠ‘åˆ¶æ´»æ€§å·²åœ¨é«”å¤–å’Œå‹•ç‰©æ¨¡å‹ä¸­å¾—åˆ°è­‰å¯¦ã€‚ç„¶è€Œï¼Œç”±æ–¼ SIV ä¸æ„ŸæŸ“äººé¡ï¼Œé€™å€‹é æ¸¬çš„ä¸»è¦æ‡‰ç”¨æ˜¯åœ¨ç¸é†«å­¸é ˜åŸŸï¼ˆéˆé•·é¡å‹•ç‰©ï¼‰æˆ–ä½œç‚º HIV ç ”ç©¶çš„å‹•ç‰©æ¨¡å‹å·¥å…·ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- é€™ä¸»è¦æ˜¯ç¸é†«å­¸/å‹•ç‰©ç ”ç©¶çš„æ‡‰ç”¨
- è©•ä¼°åœ¨ SIV æ„ŸæŸ“çš„éäººéˆé•·é¡å‹•ç‰©ä¸­çš„ç™‚æ•ˆå’Œå®‰å…¨æ€§
- ä½œç‚º HIV ç ”ç©¶å·¥å…·ï¼Œå·²æœ‰å……åˆ†çš„æ‡‰ç”¨åŸºç¤
- å°æ–¼è²“æ„›æ»‹ç—…ï¼ˆFIVï¼‰ï¼Œéœ€é€²è¡Œé¡å¤–çš„ç¨®é–“äº¤å‰åæ‡‰ç ”ç©¶


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Vismodegib]({{ "/drugs/vismodegib/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Pralatrexate]({{ "/drugs/pralatrexate/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Aluminum Oxide]({{ "/drugs/aluminum_oxide/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Salicylamide]({{ "/drugs/salicylamide/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Minoxidil]({{ "/drugs/minoxidil/" | relative_url }}) - è­‰æ“šç­‰ç´š L4

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Ritonavirè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/ritonavir/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_ritonavir,
  title = {Ritonavirè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/ritonavir/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
